107756-30-9 Usage
Uses
A 61603 is a selective α1A-adrenergic receptor agonist.
Biological Activity
Potent α -adrenoceptor agonist that is at least 35-fold more potent at α 1A than at α 1B or α 1D sites. Induces dose response increases in spontaneous Ca 2+ transients in rat ventricular myocytes in vitro (EC 50 = 6.9 nmol/L). Also available as part of the α 1 -Adrenoceptor Tocriset? .
references
[1]. knepper sm, buckner sa, brune me, et al. a-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1a receptor subtype. j pharmacol exp ther, 1995, 274(1): 97-103.[2]. meyer md, altenbach rj, hancock aa, et al. synthesis and in vitro characterization of n-[5-(4,5-dihydro-1h-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1a receptor agonist. j med chem, 1996, 39(20): 4116-4119.[3]. luo dl, gao j, fan ll, et al. receptor subtype involved in alpha 1-adrenergic receptor-mediated ca2+ signaling in cardiomyocytes. acta pharmacol sin, 2007, 28(7): 968-974.[4]. martínez-salas sg1, campos-peralta jm, pares-hipolito j, et al. alpha1a-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. auton autacoid pharmacol, 2007, 27(3): 137-142.
Check Digit Verification of cas no
The CAS Registry Mumber 107756-30-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,7,5 and 6 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 107756-30:
(8*1)+(7*0)+(6*7)+(5*7)+(4*5)+(3*6)+(2*3)+(1*0)=129
129 % 10 = 9
So 107756-30-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H19N3O3S.BrH/c1-21(19,20)17-13-10-3-2-4-11(14-15-7-8-16-14)9(10)5-6-12(13)18;/h5-6,11,17-18H,2-4,7-8H2,1H3,(H,15,16);1H
107756-30-9Relevant articles and documents
ADRENERGIC AMIDINES
-
, (2008/06/13)
Disclosed herein are adrenergic compounds represented by the formula STR1 wherein m is 0, 1 or 2; R 1, R 2, R 3 and R. sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO 2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R 1, R 2, R. sub.3 and R 7 cannot simultaneously be hydrogen or halo, and provided that when one of R 1, R 2, R 3 and R 7 is halo, the others cannot simultaneously be hydrogen and when two of R 1, R 2, R 3 and R 7 are halo, the other two cannot simultaneously be hydrogen and provided that R 1 and R 7 cannot simultaneously be methoxy each when R. sub.2 and R 3 are hydrogen; R. sub.1 and R 2 or R 2 and R 3 or R 3 and R. sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R 1 and R 2 or R 2 and R 3 or R 3 and R. sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R. sub.4 and R 5 are hydrogen or taken together form a closed ring of the formula STR2 wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R 6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.
